Study of Immunohistochemical  Markers (CK-19, CD-56, Ki-67, p53)  in Differentiating Benign and Malignant  Solitary Thyroid Nodules with special  Reference to Papillary Thyroid Carcinomas

Dwivedi, Smriti S; Khandeparkar, Siddhi Gaurish Sinai; Joshi, Avinash R; Kulkarni, M. L.; Bhayekar, Pallavi D; Jadhav, Amruta B; Nayar, Musphera; Kambale, Neelam S

doi:10.7860/jcdr/2016/22428.9114

Cited by 9 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, in addition to nuclear staining, cytoplasmic p53 staining was observed predominantly in all case groups of the present study. In the present study, the p53 staining pattern was in accordance with those reported previously [17][18][19][20][21], and the staining percentage was found to be significantly lower in the benign case group than in the malignant groups. Interpretation of this finding together with the results reported in the literature suggests that p53 is a malignity marker and plays a role in tumor pathogenesis.…”

Section: 2discussionsupporting

confidence: 93%

Tiroid papiller karsinom, papiller mikrokarsinom ve tiroid papiller karsinomun lenf nodu metastazında apoptoz ve hücre siklusu ile ilişkili belirleyicilerin (p16, p2l, p27, p53, bcl-2, bax, bcl-xl ve siklin-D1) doku microarray yöntemiyle saptanması

Akgün

Temız

Ayhan

et al. 2021

Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi

View full text Add to dashboard Cite

Bu çalışmanın amacı, tiroid papiller karsinom ve lenf nodu metastazının patogenezinde apoptoz ve hücre döngüsü ile ilişkili gen ürünlerinin rolünü belirlemektir. Gereç ve Yöntemler: Tiroid papiller karsinom (n = 35), tiroid papiller mikrokarsinom (TPMK) (n = 22), TPK-lenf nodu metastazı (TPK-LNM) (n = 12) ve adenomatöz nodülde (AN) ( n = 20) doku mikroarray yöntemi (TMA) kullanılarak p16, p21, p27, p53, bcl-2, bax, bcl-xL ve siklin D1'in immünohistokimyasal olarak boyanması incelendi. Bulgular: AN'lerin Bcl-2 boyaması, malign gruplarınkilerden önemli ölçüde farklıydı. p53, p16, p21 boyama yüzdeleri, malign gruplarda benign lezyonlara göre anlamlı olarak daha yüksekti. TPC-LNM grubu, primer tümör gruplarından daha yüksek p16 ve siklin D1 pozitifliğine sahipti. p27 boyanmasındaki en dikkat çekici fark , TPK-LNM ve TPK grupları arasındaydı. Sonuç: Hücre döngüsü düzenleyicilerinin, özellikle bcl-2 ailesinin, TPC karsinogenezinde önemli roller oynadığı sonucuna vardık. Siklin-CDK kompleksi (p16, p21, p27) üzerinde etkili olan sikline bağımlı kinaz inhibitörleri, malignite, progresyon ve kötü prognoz potansiyeli ile daha çok ilişkiliydi. p53, hem apoptozu hem de hücre döngüsünü düzenleyen proteinlerle etkileşime girerek TPC patogenezinde önemli bir rol oynar.

show abstract

Section: 2discussionsupporting

confidence: 93%

Tiroid papiller karsinom, papiller mikrokarsinom ve tiroid papiller karsinomun lenf nodu metastazında apoptoz ve hücre siklusu ile ilişkili belirleyicilerin (p16, p2l, p27, p53, bcl-2, bax, bcl-xl ve siklin-D1) doku microarray yöntemiyle saptanması

Akgün

Temız

Ayhan

et al. 2021

Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi

View full text Add to dashboard Cite

show abstract

“…In thyroid neoplasms, there are studies that analyse both the diagnostic and prognostic value of this marker. Dwivedi et al 13 analysed the expression of Ki-67 and observed greater expression of this marker in papillary thyroid carcinomas in relation to non-neoplastic lesions. Miyauchi et al 14 found that Ki-67 was an independent prognostic factor for disease-free survival.…”

Section: Introductionmentioning

confidence: 99%

Ki-67 and CK-19 are predictors of locoregional recurrence in papillary thyroid carcinoma

Viana

Filho

Francisco

et al. 2020

Acta Otorhinolaryngol Ital

View full text Add to dashboard Cite

show abstract

“…Although p53 can be assessed by molecular detection, the possibility of immunohistochemical (IHC) evaluation is an alternative testing modality, especially in those laboratories where molecular testing is limited. [11][12][13][14][15][16][17][18][19][20] To date, a few articles have found a discrepancy between IHC and p53 gene mutations, with a lack of mutations in cases that demonstrated positive p53 staining by IHC. 21,22 The majority of articles evaluated p53 immunostaining on histological thyroid samples, [10][11][12][13][14][15][16][17][18][19][20] and, to the best of our knowledge, no publications have been reported about its role in cytological samples, including liquid-based cytology (LBC).…”

Section: Introductionmentioning

confidence: 99%

p53 expression in cytology samples may represent a marker of early‐stage cancer

Policardo

Tralongo

Arciuolo

et al. 2023

Cancer Cytopathology

View full text Add to dashboard Cite

Background TP53 gene plays a major role in the negative control of cell proliferation and in the regulation of signaling cascades. TP53 mutation may have a relevant role in the malignant transformation of thyroid cells as well as thyroid tumor progression. TP53 mutation has been detected only in few well differentiated thyroid carcinomas and is absent in benign conditions. Methods A total of 162 prospective thyroid cytology and corresponding histological samples diagnosed from atypia of indeterminate significance (AUS) to malignant, were studied via immunocytochemistry for p53. Hence, 50 benign lesions (B) were used as negative control. Molecular analysis for p53 only was performed. Results The cytology resulted in 50 B, 48 AUS, 40 follicular neoplasms (FNs), 23 suspicious for malignancy (SFM), and 1 malignant (M) case. The authors reported 102 negative and 60 positive p53 cases. The 60 positive cases included 27 cases with weak and/or focal cytoplasmic positivity (+1) and 33 with cases moderate (2+) to strong (3+) cytoplasmic and/or nuclear expression. Overall, 71 cases had histology (2 B, 11 AUS, 37 FN, 20 SFM, and 1 M) including 61.7% benign and 38.2% malignant diagnoses. Only 16 of 71 (5 FN, 10 SFM, and 1 M) were p53‐positive. Furthermore, 100% AUS and 86.5% FN cases were p53‐negative, none of which had malignant histology. All p53‐positive cases were associated with a larger nodule size, tall‐cell variant subtype, multifocality, extra thyroidal infiltration, and nodal metastases. Noninvasive follicular thyroid neoplasm with papillary like nuclear features were negative for p53. Few discrepancies in p53 intensity were observed on histology; there were no differences with the molecular testing. Conclusions p53 might be useful in discriminating thyroid follicular lesions. p53 is likely to be a useful diagnostic marker in recognizing indeterminate lesions that are well‐differentiated thyroid cancers.

show abstract

Study of Immunohistochemical Markers (CK-19, CD-56, Ki-67, p53) in Differentiating Benign and Malignant Solitary Thyroid Nodules with special Reference to Papillary Thyroid Carcinomas

Cited by 9 publications

References 22 publications

Tiroid papiller karsinom, papiller mikrokarsinom ve tiroid papiller karsinomun lenf nodu metastazında apoptoz ve hücre siklusu ile ilişkili belirleyicilerin (p16, p2l, p27, p53, bcl-2, bax, bcl-xl ve siklin-D1) doku microarray yöntemiyle saptanması

Tiroid papiller karsinom, papiller mikrokarsinom ve tiroid papiller karsinomun lenf nodu metastazında apoptoz ve hücre siklusu ile ilişkili belirleyicilerin (p16, p2l, p27, p53, bcl-2, bax, bcl-xl ve siklin-D1) doku microarray yöntemiyle saptanması

Ki-67 and CK-19 are predictors of locoregional recurrence in papillary thyroid carcinoma

p53 expression in cytology samples may represent a marker of early‐stage cancer

Contact Info

Product

Resources

About